JNK signalling: a possible target to prevent neurodegeneration
- PMID: 17584114
- DOI: 10.2174/138161207780858384
JNK signalling: a possible target to prevent neurodegeneration
Abstract
The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK). JNK is an important transducing enzyme that is involved in many facets of cellular regulation including gene expression, cell proliferation and programmed cell death. The activation of JNK pathways is critical for naturally occurring cell death during development as well as for pathological death associated with neurodegenerative diseases. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies see JNK as a target to prevent cell death. Several in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with neuronal death in Parkinson's and Alzheimer's disease. So efforts are now aimed at developing chemical inhibitors of this pathway. These have proved effective in vivo, reducing brain damage and some of the symptoms of arthritis in animal models. An alternative cell penetrating peptide approach is now available, with the identification of the JNK permeable peptide inhibitor, which modifies JNK action rather than activation, preventing neuronal death with unprecedented specificity and efficacy in several experimental conditions, including two animal models of ischemia. In this review we examine in detail the role of JNK in neurodegeneration, particularly in Alzheimer's and Parkinson's disease. The possibility of intervention on the JNK pathway as a therapeutic approach is also illustrated.
Similar articles
-
Use of cell-permeable peptides to prevent neuronal degeneration.Trends Mol Med. 2004 May;10(5):239-44. doi: 10.1016/j.molmed.2004.03.008. Trends Mol Med. 2004. PMID: 15121051 Review.
-
Mixed-lineage kinases: a target for the prevention of neurodegeneration.Annu Rev Pharmacol Toxicol. 2004;44:451-74. doi: 10.1146/annurev.pharmtox.44.101802.121840. Annu Rev Pharmacol Toxicol. 2004. PMID: 14744254 Review.
-
JNK pathway as therapeutic target to prevent degeneration in the central nervous system.Adv Exp Med Biol. 2006;588:145-55. doi: 10.1007/978-0-387-34817-9_13. Adv Exp Med Biol. 2006. PMID: 17089886 Review.
-
New therapeutic strategy for Parkinson's and Alzheimer's disease.Curr Med Chem. 2010;17(25):2764-74. doi: 10.2174/092986710791859324. Curr Med Chem. 2010. PMID: 20586718 Review.
-
Dose-dependent neuroprotective effect of the JNK inhibitor Brimapitide in 5xFAD transgenic mice.Brain Res. 2020 Jan 15;1727:146587. doi: 10.1016/j.brainres.2019.146587. Epub 2019 Dec 4. Brain Res. 2020. PMID: 31811838
Cited by
-
Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death.J Biol Chem. 2012 Oct 12;287(42):35444-35453. doi: 10.1074/jbc.M112.394544. Epub 2012 Aug 23. J Biol Chem. 2012. PMID: 22918830 Free PMC article.
-
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013. J Neurosci. 2013. PMID: 23392662 Free PMC article.
-
The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.Neurotox Res. 2019 Apr;35(3):775-795. doi: 10.1007/s12640-019-0003-y. Epub 2019 Feb 1. Neurotox Res. 2019. PMID: 30707354 Review.
-
Proteasome inhibition modulates kinase activation in neural cells: relevance to ubiquitination, ribosomes, and survival.J Neurosci Res. 2009 Nov 1;87(14):3231-8. doi: 10.1002/jnr.22147. J Neurosci Res. 2009. PMID: 19565657 Free PMC article.
-
Dusp8 affects hippocampal size and behavior in mice and humans.Sci Rep. 2019 Dec 20;9(1):19483. doi: 10.1038/s41598-019-55527-7. Sci Rep. 2019. PMID: 31862894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
